Imiquimod
Overview
Imiquimod is an immune response modifier used topically to treat specific skin diseases, including actinic keratosis, superficial basal cell carcinoma, and external genital warts. It functions by stimulating the body's immune system to release cytokines, which can help destroy viral and cancerous cells.
API suppliers (13)
Suppliers of Imiquimod evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 12 of 13 suppliers.
9 of 13 hold a GMP certificate on record in the EU or UK registers
- Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
- TAPI NL BVNetherlands1 active DMF
- WAVELENGTH ENTERPRISES LTDIsrael1 active DMF GMP on record
- Teva Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
- ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
- INTERQUIM SAPeru1 active DMF GMP on record
- ACTAVIS GROUP PTC EHFIceland1 active DMF GMP on record
- SOLARA ACTIVE PHARMA SCIENCES LTDIndia1 active DMF GMP on record
- WANBURY LTDIndia1 active DMF
- USV PRIVATE LTDIndia1 active DMF GMP on record
- TAI HENG INDUSTRY CO LTD
- Cipla USA, Inc.USA
- Amino Chemicals LtdMalta GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (7 approved US products), the latest listed US patent on Imiquimod expires 30 Apr 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Imiquimod? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.